Advertisement
A vs DHR
Which Stock Would AI Choose? Agilent Technologies (A) vs. Danaher (DHR) Stock Comparison
Key Takeaways
- Agilent Technologies (A) reported stronger year-over-year revenue growth of 7.0% in its most recent quarter compared to Danaher (DHR)’s 3.5% increase.
- A trades at a lower price-to-earnings ratio than DHR, indicating a relatively more attractive valuation on current metrics.
- Both stocks have experienced notable declines year-to-date amid broader sector pressures in life sciences and diagnostics.
- DHR maintains a substantially larger market capitalization and greater business diversification across multiple platforms.
- Analyst sentiment remains constructive for A, with upcoming earnings on May 27 providing a near-term catalyst.
- Relative performance over the past twelve months has favored A over DHR.
Introduction
Agilent Technologies (A) and Danaher (DHR) operate in overlapping segments of the life sciences and diagnostics industry, making them natural points of comparison for investors seeking exposure to precision measurement, biopharmaceutical tools, and healthcare technology. Portfolio managers and traders evaluating sector rotation, valuation differentials, or relative momentum often examine these names side by side. The comparison highlights differences in scale, recent growth trajectories, and market positioning within a challenging macroeconomic environment marked by cautious capital spending in research and clinical markets.
Agilent Technologies (A) Overview and Recent Performance
Agilent Technologies (A) provides analytical instruments, reagents, and software primarily for life sciences, diagnostics, and applied chemical markets. In recent market activity, the stock has traded in a range reflecting tempered investor expectations following mixed order trends earlier in the year. First-quarter fiscal 2026 results showed reported revenue of $1.80 billion, representing 7.0% growth, with core growth of 4.4%. Strength in the clinical diagnostics segment and improving book-to-bill ratios contributed to a modest recovery in sentiment. The shares have remained below their 52-week high amid broader healthcare sector rotation, though analyst price targets suggest meaningful upside potential ahead of second-quarter results scheduled for release on May 27.
Danaher (DHR) Overview and Recent Performance
Danaher (DHR) operates a diversified portfolio spanning life sciences, diagnostics, and environmental and applied solutions through its Danaher Business System operating philosophy. Recent market activity has reflected investor caution following first-quarter 2026 results that showed revenue of $6.0 billion, up 3.5% year-over-year, with core revenue essentially flat. Adjusted earnings per share of $2.06 exceeded consensus estimates, supporting operating cash flow of $1.3 billion. The stock has traded lower year-to-date, consistent with peers facing delayed instrument purchases and slower bioprocessing recovery, though the company raised full-year adjusted earnings guidance on the back of operational discipline.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of the platform’s most suitable AI trading bots for prevailing market conditions. Tickeron offers hundreds of AI trading bots that execute strategies across thousands of tickers, yet only those demonstrating consistent performance, favorable risk-adjusted returns, and alignment with current volatility and sector trends earn placement in the trending section. Available bots span a wide array of trading styles, timeframes, and statistical profiles, with many showing win rates above 60% and varying drawdown characteristics depending on strategy parameters. This curated view allows traders to identify automated approaches that may complement fundamental stock comparisons. Review the full selection on the Trending AI Robots page.
Head-to-Head Comparison
Agilent Technologies (A) focuses on a narrower set of analytical and measurement technologies, while Danaher (DHR) benefits from broader diversification across multiple end markets and a proven acquisition integration track record. Growth drivers for A center on rebounding demand in clinical and biopharmaceutical applications, whereas DHR relies on steady recurring revenue from consumables and service contracts. Recent momentum has been modestly stronger for A, supported by order growth metrics, while DHR offers greater scale and liquidity. Risk factors for both include exposure to capital expenditure cycles in research institutions and potential regulatory shifts in diagnostics. Market sentiment remains neutral to cautious for the pair, with valuation differentials favoring A on trailing and forward earnings multiples.
Tickeron AI Verdict
Based on observable factors including more consistent recent revenue growth, lower valuation multiples, and upcoming earnings visibility, Tickeron’s AI models currently assign a modestly higher probability of favorable relative performance to Agilent Technologies (A) versus Danaher (DHR) over the near term, subject to confirmation of order trends and broader sector stability.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a StrongBuy and DHR is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 1 FA rating(s) are green whileDHR’s FA Score has 1 green FA rating(s).
- A’s FA Score: 1 green, 4 red.
- DHR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 4 TA indicator(s) are bullish while DHR’s TA Score has 5 bullish TA indicator(s).
- A’s TA Score: 4 bullish, 6 bearish.
- DHR’s TA Score: 5 bullish, 5 bearish.
Price Growth
A (@Medical Specialties) experienced а -6.37% price change this week, while DHR (@Medical Specialties) price change was -3.13% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.49%. For the same industry, the average monthly price growth was +16.29%, and the average quarterly price growth was -4.45%.
Reported Earning Dates
A is expected to report earnings on Aug 18, 2026.
DHR is expected to report earnings on Jul 28, 2026.
Industries' Descriptions
@Medical Specialties (-3.49% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| A | DHR | A / DHR | |
| Capitalization | 36.6B | 128B | 29% |
| EBITDA | 1.96B | 7.08B | 28% |
| Gain YTD | -4.404 | -20.856 | 21% |
| P/E Ratio | 26.01 | 35.04 | 74% |
| Revenue | 7.23B | 24.8B | 29% |
| Total Cash | 1.81B | 5.7B | 32% |
| Total Debt | 3.36B | 18.5B | 18% |
A | DHR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 37 | 21 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 6 Undervalued | 8 Undervalued | |
PROFIT vs RISK RATING 1..100 | 95 | 100 | |
SMR RATING 1..100 | 44 | 81 | |
PRICE GROWTH RATING 1..100 | 43 | 55 | |
P/E GROWTH RATING 1..100 | 64 | 64 | |
SEASONALITY SCORE 1..100 | 50 | 25 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (6) in the Biotechnology industry is in the same range as DHR (8) in the Medical Specialties industry. This means that A’s stock grew similarly to DHR’s over the last 12 months.
A's Profit vs Risk Rating (95) in the Biotechnology industry is in the same range as DHR (100) in the Medical Specialties industry. This means that A’s stock grew similarly to DHR’s over the last 12 months.
A's SMR Rating (44) in the Biotechnology industry is somewhat better than the same rating for DHR (81) in the Medical Specialties industry. This means that A’s stock grew somewhat faster than DHR’s over the last 12 months.
A's Price Growth Rating (43) in the Biotechnology industry is in the same range as DHR (55) in the Medical Specialties industry. This means that A’s stock grew similarly to DHR’s over the last 12 months.
A's P/E Growth Rating (64) in the Biotechnology industry is in the same range as DHR (64) in the Medical Specialties industry. This means that A’s stock grew similarly to DHR’s over the last 12 months.
| A | DHR | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 70% | 1 day ago 64% |
| Stochastic ODDS (%) | 1 day ago 65% | 1 day ago 65% |
| Momentum ODDS (%) | 1 day ago 64% | 1 day ago 58% |
| MACD ODDS (%) | 1 day ago 67% | 1 day ago 52% |
| TrendWeek ODDS (%) | 1 day ago 64% | 1 day ago 64% |
| TrendMonth ODDS (%) | 1 day ago 58% | 1 day ago 54% |
| Advances ODDS (%) | 8 days ago 60% | 8 days ago 54% |
| Declines ODDS (%) | 1 day ago 62% | 1 day ago 61% |
| BollingerBands ODDS (%) | 1 day ago 63% | 1 day ago 58% |
| Aroon ODDS (%) | 1 day ago 69% | 1 day ago 62% |
Advertisement